Stay updated with breaking news from Benjamin Cravatt. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
Searching for new ways to block the growth of cancer cells is like looking for a needle in a haystack. Tumor cells rely on thousands of proteins to function, but only a few of those proteins can be precisely targeted by drugs to treat cancer safely and effectively.
/PRNewswire/ -- Magnet Biomedicine, a biotechnology company advancing molecular glue discovery with rational selection and design, today announced a $50...
FinSMEs is the financial news site dedicated to covering venture capital, private equity, and merger and acquisition deals in real time!
Capula Management Ltd purchased a new stake in shares of FibroGen, Inc. (NASDAQ:FGEN – Free Report) in the 1st quarter, Holdings Channel reports. The fund purchased 23,520 shares of the biopharmaceutical company’s stock, valued at approximately $439,000. A number of other institutional investors and hedge funds have also recently added to or reduced their stakes […]
FibroGen (NASDAQ:FGEN – Get Free Report) was downgraded by analysts at Bank of America from a “neutral” rating to an “underperform” rating in a note issued to investors on Tuesday, MarketBeat Ratings reports. They presently have a $2.00 price target on the biopharmaceutical company’s stock, down from their prior price target of $4.00. Bank of […]